A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

NCT05585632 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
392
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

ModernaTX, Inc.